English
Chinese
Cart
No Items In Cart
NovaPure® Components
NovaPure® components have quality built in from the start. West has developed a comprehensive quality target product profile (QTPP) based on the needs of our customers and end users. Critical quality attributes (CQAs), determined with the end user in mind, have been established to help ensure quality, safety and efficacy throughout a drug product’s lifecycle.
Overview
Downloadable Resources
West Ready Pack™, FluroTec® and NovaPure® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
FluroTec technology is licensed from Daikyo Seiko, Ltd.
FluroTec technology is licensed from Daikyo Seiko, Ltd.
Related Blogs
May 18, 2021
NovaPure® 3mL Cartridge Components: Quality by Design (QbD) Principles Mitigate Risks Associated with Biologic Drugs Packaging and Delivery Systems
Globally, the market for biologic drugs is growing significantly, due to their proven ability to treat major chronic diseases, in particular those found among an increasingly aging population. Cartridge systems are very important in delivering these biologic drugs; they can be used in autoinjectors, pen injectors, and wearable devices. Since biologics drugs are very sensitive, they require highest-quality cartridge components.
March 10, 2021
Biosimilars Market Survey Brings Insight to Most Important Containment and Support Service Needs
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
April 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
May 18, 2021
NovaPure® 3mL Cartridge Components: Quality by Design (QbD) Principles Mitigate Risks Associated with Biologic Drugs Packaging and Delivery Systems
Globally, the market for biologic drugs is growing significantly, due to their proven ability to treat major chronic diseases, in particular those found among an increasingly aging population. Cartridge systems are very important in delivering these biologic drugs; they can be used in autoinjectors, pen injectors, and wearable devices. Since biologics drugs are very sensitive, they require highest-quality cartridge components.
March 10, 2021
Biosimilars Market Survey Brings Insight to Most Important Containment and Support Service Needs
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
April 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
